Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Cisplatin + Gemcitabine + Nivolumab & Bladder cancer, in September 2024, the FDA approved Cisplatin + Gemcitabine + Nivolumab for first‑line treatment of patients with unresectable or metastatic Bladder cancer, based on the phase III CheckMate 901 trial showing OS and PFS benefit versus Cisplatin + Gemcitabine alone (1, 2, 3). This approval is specifically for advanced/metastatic Bladder cancer (which includes bladder primary), in cisplatin‑eligible patients (1, 3).
Recent European reviews describe Cisplatin + Gemcitabine + Nivol…